Remdesivir for patients with COVID-19.
作者信息
Wu Peter E, Morris Andrew M
机构信息
Department of Medicine (Wu, Morris) Division of Clinical Pharmacology & Toxicology (Wu) and Division of Infectious Diseases (Morris), University of Toronto; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Infectious Diseases (Morris), Sinai Health and University Health Network, Toronto, Ont.
出版信息
CMAJ. 2021 Jan 25;193(4):E125. doi: 10.1503/cmaj.202505. Epub 2021 Jan 6.
Abstract
摘要
相似文献
1
Remdesivir for patients with COVID-19.
CMAJ. 2021 Jan 25;193(4):E125. doi: 10.1503/cmaj.202505. Epub 2021 Jan 6.
2
[Not Available].
CMAJ. 2021 Apr 6;193(14):E495-E496. doi: 10.1503/cmaj.202505-f.
3
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
4
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
Ann Intern Med. 2021 Feb;174(2):229-236. doi: 10.7326/M20-5831. Epub 2020 Oct 5.
5
Remdesivir as a broad-spectrum antiviral drug against COVID-19.
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548. doi: 10.26355/eurrev_202101_24426.
6
Safety profile of the antiviral drug remdesivir: An update.
Biomed Pharmacother. 2020 Oct;130:110532. doi: 10.1016/j.biopha.2020.110532. Epub 2020 Jul 22.
7
Remdesivir for the treatment of COVID-19 in pregnancy.
J Med Virol. 2021 Jul;93(7):4114-4119. doi: 10.1002/jmv.26986. Epub 2021 Apr 14.
8
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
Cardiovasc Hematol Disord Drug Targets. 2021;21(2):88-90. doi: 10.2174/1871529X21666210812103535.
9
Remdesivir (Veklury) for COVID-19.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):186-188.
10
Missed Opportunities on Emergency Remdesivir Use.
JAMA. 2020 Jul 28;324(4):331-332. doi: 10.1001/jama.2020.11932.
引用本文的文献
1
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.
Front Pharmacol. 2021 Jun 14;12:659577. doi: 10.3389/fphar.2021.659577. eCollection 2021.
本文引用的文献
1
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
2
Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series.
Pharmacotherapy. 2020 Nov;40(11):1166-1171. doi: 10.1002/phar.2464. Epub 2020 Oct 27.
3
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349.
4
Remdesivir for the Treatment of Covid-19 - Final Report.
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
5
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
Zotero 插件